ClinicalTrials.gg
Sign In
Drug

Adenosine A2A Receptor Antagonist NIR178 clinical trials

Also written NIR178.

studies test it
3
open now
0
in phase 3
0
first study started
2017

How each study uses Adenosine A2A Receptor Antagonist NIR178 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

NIR178
3

Studies by the year they started

3 studies that test it; most in 2017 (1)

Studies that test Adenosine A2A Receptor Antagonist NIR178, by start year
YearStudies
20171
20181
20191

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1

Who runs them

Industry 3 · Other 0

Novartis Pharmaceuticals (3)

Often tested with

Tested in the same studies.

Lacnotuzumab (1) · Spartalizumab (1)

Studies

Open first, then newest update. How each study uses Adenosine A2A Receptor Antagonist NIR178 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Given beside what is tested · 2 — Adenosine A2A Receptor Antagonist NIR178 is usual care or a partner of the new treatment